Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. United States
  4. Nasdaq
  5. Moderna, Inc.
  6. News
  7. Summary
    MRNA   US60770K1079

MODERNA, INC.

(MRNA)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Moderna : U.S. CDC advisers back J&J COVID-19 vaccine benefits amid neurological illness reports

07/22/2021 | 03:04pm EDT

July 22 (Reuters) - Despite reports of a rare neurological disorder appearing in some people who have received Johnson & Johnson's COVID-19 vaccine, the benefits of its use outweigh the risks, a U.S. Centers for Disease Control and Prevention advisory panel said on Thursday.

The U.S. Food and Drug Administration last week added a warning to its fact sheet for J&J's single-shot vaccine saying that data suggests there is an increased risk of Guillain-Barre syndrome (GBS) in the six weeks after vaccination.

The CDC advisory panel evaluated the J&J vaccine's risks and benefits after these preliminary reports of GBS from people who have gotten the shot.

Given the possible association between GBS and the vaccine, CDC will update its considerations for the use of J&J's vaccine to say that patients with a history of GBS should first look at the availability of two-shot mRNA-based vaccines from Pfizer Inc /BioNTech SE and Moderna, an agency official said.

The FDA cited 100 preliminary reports of GBS in J&J vaccine recipients including 95 serious cases that required hospitalization and one reported death.

J&J on Thursday said the known benefits on its vaccine outweigh known potential risks.

Members of a work group of the CDC Advisory Committee on Immunization Practices (ACIP) expressed "strong support" for continued use of J&J vaccine, the CDC's Sarah Mbaeyi said during the panel meeting.

The CDC will also update some of its communication materials on the vaccine, including information for medical providers on talking to patients about vaccine safety and frequently asked questions, Mbaeyi added. (Reporting by Manojna Maddipatla in Bengaluru; Editing by Will Dunham)


ę Reuters 2021
All news about MODERNA, INC.
05:26pMODERNA : U.S. CDC Says 212,564,346 Individuals Have Received At Least One Dose Of Covid-1..
RE
12:12pMODERNA : EU drugs regulator to decide on Pfizer vaccine booster in early October
RE
12:01pGLOBAL MARKETS LIVE : Valneva,Boeing, Facebook, Kubota, Otis...
11:06aASTRAZENECA : Vaccination Against Covid-19 Resumes Sept 24
AQ
05:51aMODERNA : EU regulator to decide on Pfizer booster at the start of October - source
RE
04:41aMODERNA : COVID-19 Pandemic Could Be Over Within One Year, Moderna CEO Says
MT
03:49aModerna chief executive sees pandemic over in a year - newspaper
RE
02:21aASTRAZENECA : invests in Imperial's self-amplifying RNA technology with eye on future drug..
RE
01:29aMODERNA : REFILE-Moderna chief executive sees pandemic over in a year - newspaper
RE
09/22ASTRAZENECA : Japan doubles COVID-19 vaccine donation pledge to 60 mln doses
RE
More news
Analyst Recommendations on MODERNA, INC.
More recommendations
Financials (USD)
Sales 2021 20 348 M - -
Net income 2021 12 529 M - -
Net cash 2021 12 947 M - -
P/E ratio 2021 15,3x
Yield 2021 -
Capitalization 178 B 178 B -
EV / Sales 2021 8,11x
EV / Sales 2022 7,50x
Nbr of Employees 1 300
Free-Float 90,3%
Chart MODERNA, INC.
Duration : Period :
Moderna, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends MODERNA, INC.
Short TermMid-TermLong Term
TrendsBullishBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus HOLD
Number of Analysts 16
Last Close Price 454,60 $
Average target price 306,23 $
Spread / Average Target -32,6%
EPS Revisions
Managers and Directors
StÚphane Bancel Chief Executive Officer & Director
Stephen Hoge President
David W. Meline Chief Financial Officer
Noubar B. Afeyan Chairman
Juan Andres Chief Technical Operations & Quality Officer
Sector and Competitors
1st jan.Capi. (M$)
MODERNA, INC.321.86%177 895
LONZA GROUP AG33.16%61 006
IQVIA HOLDINGS INC.44.97%49 771
CELLTRION, INC.-20.75%31 824
SEAGEN INC.-3.41%30 776
PHARMARON BEIJING CO., LTD.76.77%25 533